ReviewCancers2019
Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05590117 (The Possible Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer), which is not on this map. Cited by 68 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Possible Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer
Who cites it
68 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- European Guideline on Chronic Nausea and Vomiting-A UEG and ESNM Consensus for Clinical Management.United European gastroenterology journal · 2025Guideline
- Oral microbiome and systemic antineoplastics in cancer treatment: A systematic review.Medicina oral, patologia oral y cirugia bucal · 2022Pooled it
- Pooled it
- Photobiomodulation preconditioning for oral mucositis prevention and quality of life improvement in chemotherapy patients: a randomized clinical trial.BMC oral health · 2025Trial
- Hangeshashinto for prevention of oral mucositis in patients undergoing hematopoietic stem cell transplantation: a randomized phase II study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Trial
- Scheduling radiotherapy for patients with nasopharyngeal carcinoma in the corresponding time window can reduce radiation-induced oral mucositis: A randomized, prospective study.Cancer medicine · 2023Trial
- Muribaculum as a microbial contributor of rifaximin-induced mucosal protection during chemotherapy.Gut microbes · 2026Article
- Optimized Extraction of Medicinal Mushroom Polysaccharides and Their Protective Effects Against 5-Fluorouracil-Induced Gastrointestinal Mucositis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Panaxynol mitigates chemotherapy-induced intestinal mucositis by improving the colonic microenvironment in murine models.American journal of physiology. Gastrointestinal and liver physiology · 2026Article
- Dental management of patients with cancer across the care pathway: A scoping review of clinical protocols.Medicina oral, patologia oral y cirugia bucal · 2026Article
- Oral Microbiome Dynamics in Patients with Acute Lymphoblastic Leukemia and Oral Mucositis.Microorganisms · 2026Article
- Recombinant Molecules as a New Frontier in Mucositis Therapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Serum citrulline as a prognostic marker in patients with oropharyngeal carcinoma treated with chemoradiotherapy.Contemporary oncology (Poznan, Poland) · 2026Article
- Probiotic preparations in mitigating chemotherapy-induced oral mucositis: therapeutic efficacy, mechanisms, and clinical translation potential.Frontiers in cellular and infection microbiology · 2026Review
- Real-world management of oral mucositis/stomatitis among patients with advanced non-small cell lung cancer (NSCLC) or breast cancer (BC).Future oncology (London, England) · 2026Article
- Recent advances in oral cryotherapy for the management of anticancer therapy-induced oral mucositis.Future science OA · 2025Review
- Nutrition in Oncology: Overcoming Challenges to Optimize the Patient Journey from Prehabilitation to Rehabilitation.Oncology and therapy · 2025Review
- Gut microbiota in cancer initiation, development and therapy.Science China. Life sciences · 2025Review
- Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis.The oncologist · 2025Review
- Potentiality of Curcumin Against Radio-Chemotherapy Induced Oral Mucositis: A Review.Indian journal of surgical oncology · 2025Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucositis is one of the most common debilitating side effects related to chemotherapy (CT), radiation therapy (RT), targeted agents and immunotherapy. It is a complex process potentially involving any portion of the gastrointestinal tract and injuring the mucosa, leading to inflammatory or ulcerative lesions. Mechanisms and clinical presentation can differ according both to the anatomic site involved (oral or gastrointestinal) and the treatment received. Understanding the pathophysiology and management of mucosal injury as a secondary effect of anti-cancer treatment is an important area of clinical research. Prophylaxis, early diagnosis, and adequate management of complications are essential to increase therapeutic success and, thus, improve the survival outcomes of cancer patients. This review focuses on the pathobiology and management guidelines for mucositis, a secondary effect of old and new anti-cancer treatments, highlighting recent advances in prevention and discussing future research options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.